Exam (elaborations)
RAC 2023 US RAC Practice Exam – Questions/Answers
- Course
- Institution
RAC 2023 US RAC Practice Exam – Questions/Answers
[Show more]
Content preview
RAC 2023 US RAC Practice Exam – Questions/AnswersA physician reports to a manufacturer that a patient was hospitalized with acute sepsis after treatment with an approved device. This side effect is not listed in the package insert. This event must be reported by the manufacturer to FDA no later than:
A. 5 calendar days.
B. 15 calendar days.
C. 30 calendar days.
D. The next quarterly or annual report. - ✔ Explanation:
B. There are no 15 day reports included in MDR regulations. 15 Day reports are required b by drug reporting regulations.
The correct answer is: C
Under the IDE regulation, all of the following must be reported to the sponsor within five working days
EXCEPT:
A. A deviation from the investigational plan.
B. Withdrawal of IRB approval.
C. An unanticipated adverse device effect. D. Use of a device without informed consent. - ✔ Explanation:
B. Withdrawal of IRB approval is reported within five days.
The correct answer is C.
When design verification testing is being performed by a manufacturer, which
element is NOT included as a potential requirement under device design verification section of the QSR?
A. Identification of the design
B. Software validation
C. Identification of test methods used. D. Name of individuals performing the testing . - ✔ Explanation:
B. Software validation is generally included in design validation, not verification (820.30 (g)). The correct answer is C.
Under the statutory violations, lack of an approved PMA for a PMA device that is not exempt and is in commercial distribution is considered to be:
A. Adulteration.
B. Improper use.
C. Misbranded.
D. Fraudulent. - ✔ Explanation: D. PMA products introduced into commercial distribution without an approval
PMA are considered to be adulterated. FD&C Act 501 (f).
The correct answer is A.
A manufacturer of the following must file an IDE before conducting a human clinical study?
A. A device in commercial distribution before 28 May 1976 when used or investigated in accordance with its indications in labeling in effect at that time.
B. A device intended solely for veterinary use.
C. A custom device being studied for safety and effectiveness.
D. A device in commercial distribution before 28 May 1976 when used or investigated in accordance with its indications in labeling in effect at that time.
And a device intended solely for veterinary use. - ✔ Explanation:
C. While a custom device may be studied in humans without an IDE, if its safety and efficacy are being studied
in support of commercial marketing, an IDE must be file (21 CFR 812.2(c)(7))
The regulatory affairs professional performs all of the following prior to submitting a PMA to FDA
EXCEPT:
A Preparing criteria for the MDR report. B. Preparing a brief statement of reasons for noncompliance with regulation.
C. Identifying all omissions in PMA content.
D. Reviewing, organizing and checking adequacy of data pertaining to safety and efficacy evaluation. - ✔ Explanation:
B. This item is required by 814.20(b)
The correct answer is A
Which of the following sections is required in a PMA? A. Patent certification information.
B. A copy of quality manual.
C. An economic cost/benefit assessment.
D. A discussion of benefit and risk considerations. - ✔ Explanation:
D. See 21 CFR 814.20(b)(3)(vi)
D. A discussion of benefit and risk considerations
Subacute toxicity testing should be performed:
A. In two rodent species. B. In one rodent and one non-rodent species.
C. For a minimum of two weeks.
D. For a minimum of six months. - ✔ Explanation:
B. See ICH guideline M3 Maintenance of The ICH Guideline on Non-Clinical Safety Studies for The
Conduct of Human Clinical Trials for Pharmaceuticals.
B. In one rodent and one non-rodent species.
What FDA clearances are required to export a drug approved by FDA?
A. Certificate of Free Sale.
B. Customs Tax Stamps.
C. No clearance required.
D. FDA receipt for sample Form-484. - ✔ Explanation:
C. There are no FDA export requirements for approved products.
C. No clearance required.
Fully quality-assured individual toxicology reports are not required for submission of an initial IND application. However, finalized and fully quality assured reports should be available to FDA upon request within what period of the start of the human study?
A 90 days.
B. 120 days.
C. One year.
D. The final report is only required in the submission for the NDA - ✔ Explanation:
A See FDA "Guidance for Industry Q & A: Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products." OctoBer 2000.
The correct answer is B.
With respect to drug product distribution procedures, a distributor is required to do all of the following EXCEPT:
A. Establish a system whereby the oldest approved stock of a drug is distributed last.
B. Establish written procedures describing the distribution of drug products.
C. Establish a system whereby the oldest approved stock of a drug is distributed first.
D. Establish a system by which the distribution of each lot of drug product can be readily determined to facilitate its recall if necessary. - ✔ Explanation:
A. According to §211.150, this is not required of a distributor since this way of rotating stock would potentially allow a drug product to expire in storage while awaiting distribution.
The correct answer is A.
Because of reported dispensing errors due to the similarity of proprietary drug names, one of the companies involved has decided to quickly and voluntarily notify physicians and others responsible for providing patient care
about the issue via a "Dispensing Error Alert". In this approach, the company is NOT required to:
A. Use first class mail and number 10 white envelopes.
B. Use appropriate language on the outside of the mailing envelope that indicates the nature of the alert.
C. Notity FDA of its action prior to disseminating the dispensing alert notification.
D. Include its name and address in the upper left hand corner of the envelope. - ✔ Explanation:
Reference 21CFR §200.5.
The correct answer is C.
A regulatory affairs professional wants to schedule a pre-NDA meeting with the FDA. He or she should:
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller LeCrae. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $19.99. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
79650 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now